Top
Summary
All studies
Mortality
Ventilation
ICU
Hospitalization
Serious outcomes
Recovery
Viral clearance
RCTs
RCT mortality
Peer-reviewed
All outcomes
Feedback
Analgesics
⏵
Acetaminophen
Aspirin
Ibuprofen
Indomethacin
Antiandrogens
⏵
All
Proxalutamide
Spironolactone
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lactoferrin
Lifestyle
⏵
Diet
Exercise
Sleep
Sun
Melatonin
Metformin
Minerals
⏵
Selenium
Zinc
Molnupiravir
Monoclonals
⏵
Adintrevimab
Bamlanivimab/etesevimab
Bebtelovimab
Casirivimab/imdevimab
Sotrovimab
Tixagevimab/cilgavimab
Naso/orophar..
⏵
Alkalinization
Cetylpyridinium Chloride
Chlorhexidine
Hydrogen Peroxide
Iota-carrageenan
Nitric Oxide
Povidone-Iodine
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Quercetin
Remdesivir
Vitamins
⏵
Vitamin A
Vitamin B9
Vitamin C
Vitamin D
Other
Feedback
Home
Top
All convalescent plasma..
Feedback
Home
42 convalescent plasma COVID-19 studies
1% increased risk, RR 1.01 [0.96-1.05]
c19
early.org Sep 2023
c19
early
.org
COVID-19 treatment
research
Convalescent Plasma
Conv. Plasma
(more..)
Analgesics
⏵
Acetaminophen
Meta
Aspirin
Meta
Ibuprofen
Meta
Indomethacin
Meta
Close
Lifestyle
⏵
Diet
Meta
Exercise
Meta
Sleep
Meta
Sun
Meta
Close
Antiandrogens
⏵
All
Meta
Proxalutamide
Meta
Spironolactone
Meta
Close
Melatonin
Meta
Bromhexine
Meta
Metformin
Meta
Budesonide
Meta
Minerals
⏵
Selenium
Meta
Zinc
Meta
Close
Cannabidiol
Meta
Molnupiravir
Meta
Colchicine
Meta
Monoclonals
⏵
Adintrevimab
Meta
Bamlaniv../e..
Meta
Bebtelovimab
Meta
Casirivimab/i..
Meta
Sotrovimab
Meta
Tixagev../c..
Meta
Close
Conv. Plasma
Meta
Naso/orophar..
⏵
Alkalinization
Meta
Cetylpyridin..
Meta
Chlorhexidine
Meta
Hydrogen Per..
Meta
Iota-carragee..
Meta
Nitric Oxide
Meta
Povidone-Iod..
Meta
Close
Curcumin
Meta
Nigella Sativa
Meta
Ensovibep
Meta
Nitazoxanide
Meta
Famotidine
Meta
Paxlovid
Meta
Favipiravir
Meta
Peg.. Lambda
Meta
Fluvoxamine
Meta
Quercetin
Meta
Hydroxychlor..
Meta
Remdesivir
Meta
Ivermectin
Meta
Vitamins
⏵
Vitamin A
Meta
Vitamin B9
Meta
Vitamin C
Meta
Vitamin D
Meta
Close
Lactoferrin
Meta
Home
Adoption
Other Treatments
Outcomes in COVID-19 convalescent plasma studies
Home
Tweet
Share
@CovidAnalysis
Studies
Studies
Adoption
Feedback
Feedback
Analgesics
⏵
Acetaminophen
Aspirin
Ibuprofen
Indomethacin
Antiandrogens
⏵
All
Proxalutamide
Spironolactone
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lactoferrin
Lifestyle
⏵
Diet
Exercise
Sleep
Sun
Melatonin
Metformin
Minerals
⏵
Selenium
Zinc
Molnupiravir
Monoclonals
⏵
Adintrevimab
Bamlanivimab/etesevimab
Bebtelovimab
Casirivimab/imdevimab
Sotrovimab
Tixagevimab/cilgavimab
Naso/orophar..
⏵
Alkalinization
Cetylpyridinium Chloride
Chlorhexidine
Hydrogen Peroxide
Iota-carrageenan
Nitric Oxide
Povidone-Iodine
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Quercetin
Remdesivir
Vitamins
⏵
Vitamin A
Vitamin B9
Vitamin C
Vitamin D
All studies
Mortality
Ventilation
ICU
Hospitalization
Serious outcomes
Recovery
Viral clearance
RCTs
RCT mortality
Peer-reviewed
All outcomes
0
0.5
1
1.5+
All studies
-1%
42
24,249
Improvement, Studies, Patients
Relative Risk
Mortality
-0%
41
23,179
Ventilation
2%
14
2,626
ICU admission
-15%
6
2,275
Hospitalization
4%
12
3,290
Progression
2%
12
2,659
Recovery
-0%
8
13,798
Viral clearance
17%
6
1,021
RCTs
-0%
39
23,813
RCT mortality
0%
38
22,743
Peer-reviewed
-0%
38
23,876
Early
-36%
5
1,508
Late
-0%
37
22,741
Convalescent Plasma for COVID-19
c19
early
.org Sep 2023
Favors
conv. plasma
Favors
control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
INFANT-COVID-19
Libster (DB RCT)
50%
0.50 [0.09-2.65]
death
2/80
4/80
Improvement, RR [CI]
Treatment
Control
Balcells (RCT)
-247%
3.47 [0.35-11.9]
death
5/28
2/30
C3PO
Korley (RCT)
-396%
4.96 [0.58-42.2]
death
5/250
1/248
Alemany (DB RCT)
80%
0.20 [0.01-4.14]
death
0/188
2/188
Gharbharan (DB RCT)
-1%
1.01 [0.06-16.0]
death
1/207
1/209
Tauā
2
ā
= 0.49, Iā
2
ā
= 30.4%, p = 0.6
Early treatment
-36%
1.36 [0.44-4.17]
13/753
10/755
36% higher risk
Li (RCT)
35%
0.65 [0.27-1.39]
death
8/51
12/50
Improvement, RR [CI]
Treatment
Control
Avendaño-Solà (RCT)
88%
0.12 [0.01-2.11]
death
0/38
4/43
PLACID
Agarwal (RCT)
-7%
1.07 [0.73-1.58]
death
34/235
31/229
Bajpai (RCT)
-323%
4.23 [0.43-41.6]
death
3/14
1/15
AlQahtani (RCT)
50%
0.50 [0.05-5.08]
death
1/20
2/20
PlasmAr
Simonovich (RCT)
4%
0.96 [0.50-1.83]
death
25/228
12/105
Ray (RCT)
33%
0.67 [0.30-1.50]
death
10/40
14/40
RECOVERY
Recovery Co.. (RCT)
0%
1.00 [0.93-1.07]
death
1,399/5,795
1,408/5,763
Gonzalez
-7%
1.07 [0.76-1.50]
death
60/130
26/60
OTā
1
ā
Pouladza.. (SB RCT)
40%
0.60 [0.16-2.29]
death
3/30
5/30
Bennett-.. (DB RCT)
19%
0.81 [0.36-1.86]
death
16/59
5/15
Gharbharan (RCT)
4%
0.96 [0.25-2.41]
death
6/43
11/43
PLACOVID
Sekine (RCT)
-38%
1.38 [0.73-2.63]
death
18/80
13/80
COVIDIT
Kirenga (RCT)
-21%
1.21 [0.51-2.89]
death
10/69
8/67
CAPRI
Hsue (DB RCT)
-212%
3.12 [0.14-71.7]
death
1/16
0/18
DAWn-plasma
Devos (RCT)
1%
0.99 [0.52-1.88]
death
320 (n)
163 (n)
CONCOR-1
BƩgin (RCT)
-13%
1.13 [0.88-1.45]
death
156/625
69/313
CAPSID
Kƶrper (RCT)
37%
0.63 [0.33-1.22]
death
11/53
17/52
TSUNAMI
Menichetti (RCT)
23%
0.77 [0.39-1.49]
death
14/231
19/240
Holm (RCT)
45%
0.55 [0.11-2.84]
death
2/17
3/14
CONTAIN COVID-19
Ortigoza (DB RCT)
12%
0.88 [0.63-1.20]
death
59/462
71/462
PennCCP2
Bar (RCT)
81%
0.19 [0.04-0.84]
death
40 (n)
39 (n)
Sullivan (DB RCT)
86%
0.14 [0.01-2.75]
death
0/592
3/589
Jalili (RCT)
-45%
1.45 [0.74-2.87]
death
16/60
11/60
Baldeón (DB RCT)
12%
0.88 [0.37-2.11]
death
7/63
12/95
PROTECT-Patient
van den Berg (RCT)
17%
0.83 [0.41-1.68]
death
11/52
13/51
De Santis (RCT)
13%
0.87 [0.48-1.56]
death
11/36
25/71
Rojas (SB RCT)
-220%
3.20 [0.64-16.0]
death
46 (n)
45 (n)
COOP-COVID-19-MCTI
Song (RCT)
-52%
1.52 [0.70-3.27]
death
22/87
7/42
CORIPLASM
Lacombe (RCT)
49%
0.51 [0.20-1.32]
death
7/60
12/60
CCAP-2
Thorlaci.. (DB RCT)
-76%
1.76 [0.62-5.01]
death
15/98
4/46
PassItOn
Self (DB RCT)
-3%
1.03 [0.73-1.44]
death
89/482
80/465
REMAP-CAP
Higgins (RCT)
1%
0.99 [0.86-1.14]
death
370/944
324/790
ICU patients
Denkinger (RCT)
8%
0.92 [0.75-1.11]
death
68 (n)
66 (n)
CSSC-004
Baksh (DB RCT)
-1%
1.01 [0.94-1.09]
no recov.
381/538
381/532
Alshamrani (PSM)
-14%
1.14 [0.79-1.45]
death
24/41
108/205
Krishnan
-270%
3.70 [0.90-15.8]
death
case control
Tauā
2
ā
= 0.00, Iā
2
ā
= 0.0%, p = 0.85
Late treatment
-0%
1.00 [0.96-1.05]
2,789/11,763
2,711/10,978
0% higher risk
All studies
-1%
1.01 [0.96-1.05]
2,802/12,516
2,721/11,733
1% higher risk
42 convalescent plasma COVID-19 studies
c19
early
.org Sep 2023
Tauā
2
ā
= 0.00, Iā
2
ā
= 0.0%, p = 0.82
Effect extraction pre-specified
(most serious outcome)
ā
1
ā
OT: comparison with other treatment
Favors conv. plasma
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
INFANT-COVID-19
Libster (DB RCT)
50%
0.50 [0.09-2.65]
2/80
4/80
Improvement, RR [CI]
Treatment
Control
Balcells (RCT)
-247%
3.47 [0.35-11.9]
5/28
2/30
C3PO
Korley (RCT)
-396%
4.96 [0.58-42.2]
5/250
1/248
Alemany (DB RCT)
80%
0.20 [0.01-4.14]
0/188
2/188
Gharbharan (DB RCT)
-1%
1.01 [0.06-16.0]
1/207
1/209
Tauā
2
ā
= 0.49, Iā
2
ā
= 30.4%, p = 0.6
Early treatment
-36%
1.36 [0.44-4.17]
13/753
10/755
36% higher risk
Li (RCT)
35%
0.65 [0.27-1.39]
8/51
12/50
Improvement, RR [CI]
Treatment
Control
Avendaño-Solà (RCT)
88%
0.12 [0.01-2.11]
0/38
4/43
PLACID
Agarwal (RCT)
-7%
1.07 [0.73-1.58]
34/235
31/229
Bajpai (RCT)
-323%
4.23 [0.43-41.6]
3/14
1/15
AlQahtani (RCT)
50%
0.50 [0.05-5.08]
1/20
2/20
PlasmAr
Simonovich (RCT)
4%
0.96 [0.50-1.83]
25/228
12/105
Ray (RCT)
33%
0.67 [0.30-1.50]
10/40
14/40
RECOVERY
Recovery Co.. (RCT)
0%
1.00 [0.93-1.07]
1,399/5,795
1,408/5,763
Gonzalez
-7%
1.07 [0.76-1.50]
60/130
26/60
OTā
1
ā
Pouladza.. (SB RCT)
40%
0.60 [0.16-2.29]
3/30
5/30
Bennett-.. (DB RCT)
19%
0.81 [0.36-1.86]
16/59
5/15
Gharbharan (RCT)
4%
0.96 [0.25-2.41]
6/43
11/43
PLACOVID
Sekine (RCT)
-38%
1.38 [0.73-2.63]
18/80
13/80
COVIDIT
Kirenga (RCT)
-21%
1.21 [0.51-2.89]
10/69
8/67
CAPRI
Hsue (DB RCT)
-212%
3.12 [0.14-71.7]
1/16
0/18
DAWn-plasma
Devos (RCT)
1%
0.99 [0.52-1.88]
320 (n)
163 (n)
CONCOR-1
BƩgin (RCT)
-13%
1.13 [0.88-1.45]
156/625
69/313
CAPSID
Kƶrper (RCT)
37%
0.63 [0.33-1.22]
11/53
17/52
TSUNAMI
Menichetti (RCT)
23%
0.77 [0.39-1.49]
14/231
19/240
Holm (RCT)
45%
0.55 [0.11-2.84]
2/17
3/14
CONTAIN COVID-19
Ortigoza (DB RCT)
12%
0.88 [0.63-1.20]
59/462
71/462
PennCCP2
Bar (RCT)
81%
0.19 [0.04-0.84]
40 (n)
39 (n)
Sullivan (DB RCT)
86%
0.14 [0.01-2.75]
0/592
3/589
Jalili (RCT)
-45%
1.45 [0.74-2.87]
16/60
11/60
Baldeón (DB RCT)
12%
0.88 [0.37-2.11]
7/63
12/95
PROTECT-Patient
van den Berg (RCT)
17%
0.83 [0.41-1.68]
11/52
13/51
De Santis (RCT)
13%
0.87 [0.48-1.56]
11/36
25/71
Rojas (SB RCT)
-220%
3.20 [0.64-16.0]
46 (n)
45 (n)
COOP-COVID-19-MCTI
Song (RCT)
-52%
1.52 [0.70-3.27]
22/87
7/42
CORIPLASM
Lacombe (RCT)
49%
0.51 [0.20-1.32]
7/60
12/60
CCAP-2
Thorlaci.. (DB RCT)
-76%
1.76 [0.62-5.01]
15/98
4/46
PassItOn
Self (DB RCT)
-3%
1.03 [0.73-1.44]
89/482
80/465
REMAP-CAP
Higgins (RCT)
1%
0.99 [0.86-1.14]
370/944
324/790
ICU patients
Denkinger (RCT)
8%
0.92 [0.75-1.11]
68 (n)
66 (n)
Alshamrani (PSM)
-14%
1.14 [0.79-1.45]
24/41
108/205
Krishnan
-270%
3.70 [0.90-15.8]
case control
Tauā
2
ā
= 0.00, Iā
2
ā
= 0.0%, p = 0.94
Late treatment
-0%
1.00 [0.95-1.05]
2,408/11,225
2,330/10,446
0% higher risk
All studies
-0%
1.00 [0.96-1.05]
2,421/11,978
2,340/11,201
0% higher risk
41 convalescent plasma COVID-19 mortality results
c19
early
.org Sep 2023
Tauā
2
ā
= 0.00, Iā
2
ā
= 0.0%, p = 0.91
ā
1
ā
OT: comparison with other treatment
Favors conv. plasma
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
INFANT-COVID-19
Libster (DB RCT)
50%
0.50 [0.09-2.65]
2/80
4/80
Improvement, RR [CI]
Treatment
Control
Balcells (RCT)
-163%
2.63 [0.43-9.10]
5/28
2/30
Gharbharan (DB RCT)
67%
0.33 [0.01-8.16]
0/207
1/209
Tauā
2
ā
= 0.30, Iā
2
ā
= 22.8%, p = 1.
Early treatment
0%
1.00 [0.28-3.54]
7/315
7/319
0% lower risk
PLACID
Agarwal (RCT)
1%
0.99 [0.54-1.81]
19/227
19/224
Improvement, RR [CI]
Treatment
Control
Bajpai (RCT)
-221%
3.21 [0.38-27.4]
3/14
1/15
AlQahtani (RCT)
33%
0.67 [0.22-2.01]
4/20
6/20
CAPRI
Hsue (DB RCT)
-425%
5.25 [0.27-102]
2/16
0/18
DAWn-plasma
Devos (RCT)
-8%
1.08 [0.65-1.80]
320 (n)
163 (n)
TSUNAMI
Menichetti (RCT)
-4%
1.04 [0.62-1.75]
25/231
25/240
Holm (RCT)
69%
0.31 [0.01-7.09]
0/17
1/14
PennCCP2
Bar (RCT)
51%
0.49 [0.18-1.30]
5/40
10/39
PROTECT-Patient
van den Berg (RCT)
67%
0.33 [0.04-3.04]
1/52
3/51
CCAP-2
Thorlaci.. (DB RCT)
-37%
1.37 [0.29-6.52]
6/94
2/43
Denkinger (RCT)
-2%
1.02 [0.59-1.77]
19/68
18/66
Tauā
2
ā
= 0.00, Iā
2
ā
= 0.0%, p = 0.87
Late treatment
2%
0.98 [0.76-1.25]
84/1,099
85/893
2% lower risk
All studies
2%
0.98 [0.77-1.25]
91/1,414
92/1,212
2% lower risk
14 convalescent plasma COVID-19 mechanical ventilation results
c19
early
.org Sep 2023
Tauā
2
ā
= 0.00, Iā
2
ā
= 0.0%, p = 0.89
Favors conv. plasma
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
INFANT-COVID-19
Libster (DB RCT)
67%
0.33 [0.07-1.60]
2/80
6/80
Improvement, RR [CI]
Treatment
Control
Tauā
2
ā
= 0.00, Iā
2
ā
= 0.0%, p = 0.17
Early treatment
67%
0.33 [0.07-1.60]
2/80
6/80
67% lower risk
DAWn-plasma
Devos (RCT)
0%
1.00 [0.74-1.34]
320 (n)
163 (n)
Improvement, RR [CI]
Treatment
Control
Sullivan (DB RCT)
25%
0.75 [0.17-3.32]
3/592
4/589
Jalili (RCT)
-8%
1.08 [0.72-1.63]
27/60
25/60
CCAP-2
Thorlaci.. (DB RCT)
-31%
1.31 [0.45-3.82]
12/89
4/39
Alshamrani (PSM)
-43%
1.43 [1.13-1.80]
37 (n)
166 (n)
Tauā
2
ā
= 0.00, Iā
2
ā
= 4.8%, p = 0.036
Late treatment
-20%
1.20 [1.01-1.43]
42/1,098
33/1,017
20% higher risk
All studies
-15%
1.15 [0.92-1.44]
44/1,178
39/1,097
15% higher risk
6 convalescent plasma COVID-19 ICU results
c19
early
.org Sep 2023
Tauā
2
ā
= 0.02, Iā
2
ā
= 26.5%, p = 0.23
Favors conv. plasma
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
C3PO
Korley (RCT)
10%
0.90 [0.64-1.26]
hosp.
51/257
56/254
Improvement, RR [CI]
Treatment
Control
Alemany (DB RCT)
-5%
1.05 [0.60-1.84]
hosp.
22/188
21/188
Gharbharan (DB RCT)
39%
0.61 [0.28-1.34]
hosp.
10/207
18/209
Tauā
2
ā
= 0.00, Iā
2
ā
= 0.0%, p = 0.39
Early treatment
11%
0.89 [0.68-1.16]
83/652
95/651
11% lower risk
Bajpai (RCT)
25%
0.75 [0.55-1.04]
hosp. time
14 (n)
15 (n)
Improvement, RR [CI]
Treatment
Control
AlQahtani (RCT)
22%
0.78 [0.57-1.07]
hosp. time
20 (n)
20 (n)
Pouladza.. (SB RCT)
-30%
1.30 [0.99-1.71]
hosp. time
30 (n)
30 (n)
PLACOVID
Sekine (RCT)
-67%
1.67 [0.01-470]
hosp. time
80 (n)
80 (n)
Holm (RCT)
-62%
1.62 [0.76-3.46]
hosp. time
17 (n)
14 (n)
Sullivan (DB RCT)
54%
0.46 [0.26-0.80]
hosp.
17/592
37/589
Jalili (RCT)
-10%
1.10 [0.89-1.36]
hosp. time
60 (n)
60 (n)
CORIPLASM
Lacombe (RCT)
-7%
1.07 [0.00-9700]
hosp. time
60 (n)
60 (n)
Alshamrani (PSM)
-32%
1.32 [1.07-1.63]
hosp. time
41 (n)
205 (n)
Tauā
2
ā
= 0.06, Iā
2
ā
= 67.1%, p = 0.93
Late treatment
1%
0.99 [0.78-1.24]
17/914
37/1,073
1% lower risk
All studies
4%
0.96 [0.80-1.16]
100/1,566
132/1,724
4% lower risk
12 convalescent plasma COVID-19 hospitalization results
c19
early
.org Sep 2023
Tauā
2
ā
= 0.05, Iā
2
ā
= 59.4%, p = 0.71
Favors conv. plasma
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
INFANT-COVID-19
Libster (DB RCT)
50%
0.50 [0.09-2.65]
death
2/80
4/80
Improvement, RR [CI]
Treatment
Control
Balcells (RCT)
-247%
3.47 [0.35-11.9]
death
5/28
2/30
C3PO
Korley (RCT)
-396%
4.96 [0.58-42.2]
death
5/250
1/248
Alemany (DB RCT)
80%
0.20 [0.01-4.14]
death
0/188
2/188
Gharbharan (DB RCT)
-1%
1.01 [0.06-16.0]
death
1/207
1/209
Tauā
2
ā
= 0.49, Iā
2
ā
= 30.4%, p = 0.6
Early treatment
-36%
1.36 [0.44-4.17]
13/753
10/755
36% higher risk
Li (RCT)
35%
0.65 [0.27-1.39]
death
8/51
12/50
Improvement, RR [CI]
Treatment
Control
Avendaño-Solà (RCT)
88%
0.12 [0.01-2.11]
death
0/38
4/43
PLACID
Agarwal (RCT)
-7%
1.07 [0.73-1.58]
death
34/235
31/229
Bajpai (RCT)
-323%
4.23 [0.43-41.6]
death
3/14
1/15
AlQahtani (RCT)
50%
0.50 [0.05-5.08]
death
1/20
2/20
PlasmAr
Simonovich (RCT)
4%
0.96 [0.50-1.83]
death
25/228
12/105
Ray (RCT)
33%
0.67 [0.30-1.50]
death
10/40
14/40
RECOVERY
Recovery Co.. (RCT)
0%
1.00 [0.93-1.07]
death
1,399/5,795
1,408/5,763
Gonzalez
-7%
1.07 [0.76-1.50]
death
60/130
26/60
OTā
1
ā
Pouladza.. (SB RCT)
40%
0.60 [0.16-2.29]
death
3/30
5/30
Bennett-.. (DB RCT)
19%
0.81 [0.36-1.86]
death
16/59
5/15
Gharbharan (RCT)
4%
0.96 [0.25-2.41]
death
6/43
11/43
PLACOVID
Sekine (RCT)
-38%
1.38 [0.73-2.63]
death
18/80
13/80
COVIDIT
Kirenga (RCT)
-21%
1.21 [0.51-2.89]
death
10/69
8/67
CAPRI
Hsue (DB RCT)
-212%
3.12 [0.14-71.7]
death
1/16
0/18
DAWn-plasma
Devos (RCT)
1%
0.99 [0.52-1.88]
death
320 (n)
163 (n)
CONCOR-1
BƩgin (RCT)
-13%
1.13 [0.88-1.45]
death
156/625
69/313
CAPSID
Kƶrper (RCT)
37%
0.63 [0.33-1.22]
death
11/53
17/52
TSUNAMI
Menichetti (RCT)
23%
0.77 [0.39-1.49]
death
14/231
19/240
Holm (RCT)
45%
0.55 [0.11-2.84]
death
2/17
3/14
CONTAIN COVID-19
Ortigoza (DB RCT)
12%
0.88 [0.63-1.20]
death
59/462
71/462
PennCCP2
Bar (RCT)
81%
0.19 [0.04-0.84]
death
40 (n)
39 (n)
Sullivan (DB RCT)
86%
0.14 [0.01-2.75]
death
0/592
3/589
Jalili (RCT)
-45%
1.45 [0.74-2.87]
death
16/60
11/60
Baldeón (DB RCT)
12%
0.88 [0.37-2.11]
death
7/63
12/95
PROTECT-Patient
van den Berg (RCT)
17%
0.83 [0.41-1.68]
death
11/52
13/51
De Santis (RCT)
13%
0.87 [0.48-1.56]
death
11/36
25/71
Rojas (SB RCT)
-220%
3.20 [0.64-16.0]
death
46 (n)
45 (n)
COOP-COVID-19-MCTI
Song (RCT)
-52%
1.52 [0.70-3.27]
death
22/87
7/42
CORIPLASM
Lacombe (RCT)
49%
0.51 [0.20-1.32]
death
7/60
12/60
CCAP-2
Thorlaci.. (DB RCT)
-76%
1.76 [0.62-5.01]
death
15/98
4/46
PassItOn
Self (DB RCT)
-3%
1.03 [0.73-1.44]
death
89/482
80/465
REMAP-CAP
Higgins (RCT)
1%
0.99 [0.86-1.14]
death
370/944
324/790
ICU patients
Denkinger (RCT)
8%
0.92 [0.75-1.11]
death
68 (n)
66 (n)
Alshamrani (PSM)
-14%
1.14 [0.79-1.45]
death
24/41
108/205
Krishnan
-270%
3.70 [0.90-15.8]
death
case control
Tauā
2
ā
= 0.00, Iā
2
ā
= 0.0%, p = 0.94
Late treatment
-0%
1.00 [0.95-1.05]
2,408/11,225
2,330/10,446
0% higher risk
All studies
-0%
1.00 [0.96-1.05]
2,421/11,978
2,340/11,201
0% higher risk
41 convalescent plasma COVID-19 serious outcomes
c19
early
.org Sep 2023
Tauā
2
ā
= 0.00, Iā
2
ā
= 0.0%, p = 0.91
Effect extraction pre-specified
(most serious outcome)
ā
1
ā
OT: comparison with other treatment
Favors conv. plasma
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Alemany (DB RCT)
-5%
1.05 [0.85-1.30]
no recov.
188 (n)
188 (n)
Improvement, RR [CI]
Treatment
Control
Gharbharan (DB RCT)
-1%
1.01 [0.88-1.16]
no recov.
137/207
137/209
Tauā
2
ā
= 0.00, Iā
2
ā
= 0.0%, p = 0.73
Early treatment
-2%
1.02 [0.91-1.15]
137/395
137/397
2% higher risk
RECOVERY
Recovery Co.. (RCT)
-1%
1.01 [0.97-1.06]
no disch.
1,963/5,795
1,941/5,763
Improvement, RR [CI]
Treatment
Control
Gharbharan (RCT)
12%
0.88 [0.49-1.60]
no disch.
43 (n)
43 (n)
CAPSID
Kƶrper (RCT)
16%
0.84 [0.62-1.14]
no recov.
30/53
35/52
PROTECT-Patient
van den Berg (RCT)
-3%
1.03 [0.62-1.71]
no disch.
18/46
19/50
Rojas (SB RCT)
38%
0.62 [0.40-0.97]
no disch.
46 (n)
45 (n)
CSSC-004
Baksh (DB RCT)
-1%
1.01 [0.94-1.09]
no recov.
381/538
381/532
Tauā
2
ā
= 0.00, Iā
2
ā
= 16.3%, p = 0.85
Late treatment
1%
0.99 [0.94-1.05]
2,392/6,521
2,376/6,485
1% lower risk
All studies
-0%
1.00 [0.97-1.04]
2,529/6,916
2,513/6,882
0% higher risk
8 convalescent plasma COVID-19 recovery results
c19
early
.org Sep 2023
Tauā
2
ā
= 0.00, Iā
2
ā
= 0.0%, p = 0.85
Favors conv. plasma
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Alemany (DB RCT)
-4%
1.04 [0.97-1.11]
viral load
188 (n)
188 (n)
Improvement, RR [CI]
Treatment
Control
Tauā
2
ā
= 0.00, Iā
2
ā
= 0.0%, p = 0.33
Early treatment
-4%
1.04 [0.97-1.11]
0/188
0/188
4% higher risk
Li (RCT)
76%
0.24 [0.07-0.64]
viral+
4/26
15/23
Improvement, RR [CI]
Treatment
Control
PLACID
Agarwal (RCT)
28%
0.72 [0.55-0.95]
viral+
56/173
76/169
Bajpai (RCT)
32%
0.68 [0.42-1.09]
viral load
14 (n)
15 (n)
COVIDIT
Kirenga (RCT)
-50%
1.50 [0.81-2.77]
viral time
67 (n)
67 (n)
Rojas (SB RCT)
-25%
1.25 [0.36-4.33]
viral+
46 (n)
45 (n)
Tauā
2
ā
= 0.15, Iā
2
ā
= 65.5%, p = 0.22
Late treatment
25%
0.75 [0.48-1.18]
60/326
91/319
25% lower risk
All studies
17%
0.83 [0.60-1.15]
60/514
91/507
17% lower risk
6 convalescent plasma COVID-19 viral clearance results
c19
early
.org Sep 2023
Tauā
2
ā
= 0.09, Iā
2
ā
= 74.8%, p = 0.26
Favors conv. plasma
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
INFANT-COVID-19
Libster (DB RCT)
50%
0.50 [0.09-2.65]
death
2/80
4/80
Improvement, RR [CI]
Treatment
Control
Balcells (RCT)
-247%
3.47 [0.35-11.9]
death
5/28
2/30
C3PO
Korley (RCT)
-396%
4.96 [0.58-42.2]
death
5/250
1/248
Alemany (DB RCT)
80%
0.20 [0.01-4.14]
death
0/188
2/188
Gharbharan (DB RCT)
-1%
1.01 [0.06-16.0]
death
1/207
1/209
Tauā
2
ā
= 0.49, Iā
2
ā
= 30.4%, p = 0.6
Early treatment
-36%
1.36 [0.44-4.17]
13/753
10/755
36% higher risk
Li (RCT)
35%
0.65 [0.27-1.39]
death
8/51
12/50
Improvement, RR [CI]
Treatment
Control
Avendaño-Solà (RCT)
88%
0.12 [0.01-2.11]
death
0/38
4/43
PLACID
Agarwal (RCT)
-7%
1.07 [0.73-1.58]
death
34/235
31/229
Bajpai (RCT)
-323%
4.23 [0.43-41.6]
death
3/14
1/15
AlQahtani (RCT)
50%
0.50 [0.05-5.08]
death
1/20
2/20
PlasmAr
Simonovich (RCT)
4%
0.96 [0.50-1.83]
death
25/228
12/105
Ray (RCT)
33%
0.67 [0.30-1.50]
death
10/40
14/40
RECOVERY
Recovery Co.. (RCT)
0%
1.00 [0.93-1.07]
death
1,399/5,795
1,408/5,763
Pouladza.. (SB RCT)
40%
0.60 [0.16-2.29]
death
3/30
5/30
Bennett-.. (DB RCT)
19%
0.81 [0.36-1.86]
death
16/59
5/15
Gharbharan (RCT)
4%
0.96 [0.25-2.41]
death
6/43
11/43
PLACOVID
Sekine (RCT)
-38%
1.38 [0.73-2.63]
death
18/80
13/80
COVIDIT
Kirenga (RCT)
-21%
1.21 [0.51-2.89]
death
10/69
8/67
CAPRI
Hsue (DB RCT)
-212%
3.12 [0.14-71.7]
death
1/16
0/18
DAWn-plasma
Devos (RCT)
1%
0.99 [0.52-1.88]
death
320 (n)
163 (n)
CONCOR-1
BƩgin (RCT)
-13%
1.13 [0.88-1.45]
death
156/625
69/313
CAPSID
Kƶrper (RCT)
37%
0.63 [0.33-1.22]
death
11/53
17/52
TSUNAMI
Menichetti (RCT)
23%
0.77 [0.39-1.49]
death
14/231
19/240
Holm (RCT)
45%
0.55 [0.11-2.84]
death
2/17
3/14
CONTAIN COVID-19
Ortigoza (DB RCT)
12%
0.88 [0.63-1.20]
death
59/462
71/462
PennCCP2
Bar (RCT)
81%
0.19 [0.04-0.84]
death
40 (n)
39 (n)
Sullivan (DB RCT)
86%
0.14 [0.01-2.75]
death
0/592
3/589
Jalili (RCT)
-45%
1.45 [0.74-2.87]
death
16/60
11/60
Baldeón (DB RCT)
12%
0.88 [0.37-2.11]
death
7/63
12/95
PROTECT-Patient
van den Berg (RCT)
17%
0.83 [0.41-1.68]
death
11/52
13/51
De Santis (RCT)
13%
0.87 [0.48-1.56]
death
11/36
25/71
Rojas (SB RCT)
-220%
3.20 [0.64-16.0]
death
46 (n)
45 (n)
COOP-COVID-19-MCTI
Song (RCT)
-52%
1.52 [0.70-3.27]
death
22/87
7/42
CORIPLASM
Lacombe (RCT)
49%
0.51 [0.20-1.32]
death
7/60
12/60
CCAP-2
Thorlaci.. (DB RCT)
-76%
1.76 [0.62-5.01]
death
15/98
4/46
PassItOn
Self (DB RCT)
-3%
1.03 [0.73-1.44]
death
89/482
80/465
REMAP-CAP
Higgins (RCT)
1%
0.99 [0.86-1.14]
death
370/944
324/790
ICU patients
Denkinger (RCT)
8%
0.92 [0.75-1.11]
death
68 (n)
66 (n)
CSSC-004
Baksh (DB RCT)
-1%
1.01 [0.94-1.09]
no recov.
381/538
381/532
Tauā
2
ā
= 0.00, Iā
2
ā
= 0.0%, p = 0.99
Late treatment
0%
1.00 [0.96-1.04]
2,705/11,592
2,577/10,713
0% lower risk
All studies
-0%
1.00 [0.96-1.04]
2,718/12,345
2,587/11,468
0% higher risk
39 convalescent plasma COVID-19 Randomized Controlled Trials
c19
early
.org Sep 2023
Tauā
2
ā
= 0.00, Iā
2
ā
= 0.0%, p = 0.99
Effect extraction pre-specified
(most serious outcome)
Favors conv. plasma
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
INFANT-COVID-19
Libster (DB RCT)
50%
0.50 [0.09-2.65]
2/80
4/80
Improvement, RR [CI]
Treatment
Control
Balcells (RCT)
-247%
3.47 [0.35-11.9]
5/28
2/30
C3PO
Korley (RCT)
-396%
4.96 [0.58-42.2]
5/250
1/248
Alemany (DB RCT)
80%
0.20 [0.01-4.14]
0/188
2/188
Gharbharan (DB RCT)
-1%
1.01 [0.06-16.0]
1/207
1/209
Tauā
2
ā
= 0.49, Iā
2
ā
= 30.4%, p = 0.6
Early treatment
-36%
1.36 [0.44-4.17]
13/753
10/755
36% higher risk
Li (RCT)
35%
0.65 [0.27-1.39]
8/51
12/50
Improvement, RR [CI]
Treatment
Control
Avendaño-Solà (RCT)
88%
0.12 [0.01-2.11]
0/38
4/43
PLACID
Agarwal (RCT)
-7%
1.07 [0.73-1.58]
34/235
31/229
Bajpai (RCT)
-323%
4.23 [0.43-41.6]
3/14
1/15
AlQahtani (RCT)
50%
0.50 [0.05-5.08]
1/20
2/20
PlasmAr
Simonovich (RCT)
4%
0.96 [0.50-1.83]
25/228
12/105
Ray (RCT)
33%
0.67 [0.30-1.50]
10/40
14/40
RECOVERY
Recovery Co.. (RCT)
0%
1.00 [0.93-1.07]
1,399/5,795
1,408/5,763
Pouladza.. (SB RCT)
40%
0.60 [0.16-2.29]
3/30
5/30
Bennett-.. (DB RCT)
19%
0.81 [0.36-1.86]
16/59
5/15
Gharbharan (RCT)
4%
0.96 [0.25-2.41]
6/43
11/43
PLACOVID
Sekine (RCT)
-38%
1.38 [0.73-2.63]
18/80
13/80
COVIDIT
Kirenga (RCT)
-21%
1.21 [0.51-2.89]
10/69
8/67
CAPRI
Hsue (DB RCT)
-212%
3.12 [0.14-71.7]
1/16
0/18
DAWn-plasma
Devos (RCT)
1%
0.99 [0.52-1.88]
320 (n)
163 (n)
CONCOR-1
BƩgin (RCT)
-13%
1.13 [0.88-1.45]
156/625
69/313
CAPSID
Kƶrper (RCT)
37%
0.63 [0.33-1.22]
11/53
17/52
TSUNAMI
Menichetti (RCT)
23%
0.77 [0.39-1.49]
14/231
19/240
Holm (RCT)
45%
0.55 [0.11-2.84]
2/17
3/14
CONTAIN COVID-19
Ortigoza (DB RCT)
12%
0.88 [0.63-1.20]
59/462
71/462
PennCCP2
Bar (RCT)
81%
0.19 [0.04-0.84]
40 (n)
39 (n)
Sullivan (DB RCT)
86%
0.14 [0.01-2.75]
0/592
3/589
Jalili (RCT)
-45%
1.45 [0.74-2.87]
16/60
11/60
Baldeón (DB RCT)
12%
0.88 [0.37-2.11]
7/63
12/95
PROTECT-Patient
van den Berg (RCT)
17%
0.83 [0.41-1.68]
11/52
13/51
De Santis (RCT)
13%
0.87 [0.48-1.56]
11/36
25/71
Rojas (SB RCT)
-220%
3.20 [0.64-16.0]
46 (n)
45 (n)
COOP-COVID-19-MCTI
Song (RCT)
-52%
1.52 [0.70-3.27]
22/87
7/42
CORIPLASM
Lacombe (RCT)
49%
0.51 [0.20-1.32]
7/60
12/60
CCAP-2
Thorlaci.. (DB RCT)
-76%
1.76 [0.62-5.01]
15/98
4/46
PassItOn
Self (DB RCT)
-3%
1.03 [0.73-1.44]
89/482
80/465
REMAP-CAP
Higgins (RCT)
1%
0.99 [0.86-1.14]
370/944
324/790
ICU patients
Denkinger (RCT)
8%
0.92 [0.75-1.11]
68 (n)
66 (n)
Tauā
2
ā
= 0.00, Iā
2
ā
= 0.0%, p = 0.86
Late treatment
0%
1.00 [0.95-1.05]
2,324/11,054
2,196/10,181
0% lower risk
All studies
0%
1.00 [0.95-1.05]
2,337/11,807
2,206/10,936
0% lower risk
38 convalescent plasma COVID-19 RCT mortality results
c19
early
.org Sep 2023
Tauā
2
ā
= 0.00, Iā
2
ā
= 0.0%, p = 0.89
Favors conv. plasma
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
INFANT-COVID-19
Libster (DB RCT)
50%
0.50 [0.09-2.65]
death
2/80
4/80
Improvement, RR [CI]
Treatment
Control
Balcells (RCT)
-247%
3.47 [0.35-11.9]
death
5/28
2/30
C3PO
Korley (RCT)
-396%
4.96 [0.58-42.2]
death
5/250
1/248
Alemany (DB RCT)
80%
0.20 [0.01-4.14]
death
0/188
2/188
Gharbharan (DB RCT)
-1%
1.01 [0.06-16.0]
death
1/207
1/209
Tauā
2
ā
= 0.49, Iā
2
ā
= 30.4%, p = 0.6
Early treatment
-36%
1.36 [0.44-4.17]
13/753
10/755
36% higher risk
Li (RCT)
35%
0.65 [0.27-1.39]
death
8/51
12/50
Improvement, RR [CI]
Treatment
Control
Avendaño-Solà (RCT)
88%
0.12 [0.01-2.11]
death
0/38
4/43
PLACID
Agarwal (RCT)
-7%
1.07 [0.73-1.58]
death
34/235
31/229
AlQahtani (RCT)
50%
0.50 [0.05-5.08]
death
1/20
2/20
PlasmAr
Simonovich (RCT)
4%
0.96 [0.50-1.83]
death
25/228
12/105
Ray (RCT)
33%
0.67 [0.30-1.50]
death
10/40
14/40
RECOVERY
Recovery Co.. (RCT)
0%
1.00 [0.93-1.07]
death
1,399/5,795
1,408/5,763
Pouladza.. (SB RCT)
40%
0.60 [0.16-2.29]
death
3/30
5/30
Bennett-.. (DB RCT)
19%
0.81 [0.36-1.86]
death
16/59
5/15
Gharbharan (RCT)
4%
0.96 [0.25-2.41]
death
6/43
11/43
PLACOVID
Sekine (RCT)
-38%
1.38 [0.73-2.63]
death
18/80
13/80
COVIDIT
Kirenga (RCT)
-21%
1.21 [0.51-2.89]
death
10/69
8/67
DAWn-plasma
Devos (RCT)
1%
0.99 [0.52-1.88]
death
320 (n)
163 (n)
CONCOR-1
BƩgin (RCT)
-13%
1.13 [0.88-1.45]
death
156/625
69/313
CAPSID
Kƶrper (RCT)
37%
0.63 [0.33-1.22]
death
11/53
17/52
TSUNAMI
Menichetti (RCT)
23%
0.77 [0.39-1.49]
death
14/231
19/240
Holm (RCT)
45%
0.55 [0.11-2.84]
death
2/17
3/14
CONTAIN COVID-19
Ortigoza (DB RCT)
12%
0.88 [0.63-1.20]
death
59/462
71/462
PennCCP2
Bar (RCT)
81%
0.19 [0.04-0.84]
death
40 (n)
39 (n)
Sullivan (DB RCT)
86%
0.14 [0.01-2.75]
death
0/592
3/589
Jalili (RCT)
-45%
1.45 [0.74-2.87]
death
16/60
11/60
Baldeón (DB RCT)
12%
0.88 [0.37-2.11]
death
7/63
12/95
PROTECT-Patient
van den Berg (RCT)
17%
0.83 [0.41-1.68]
death
11/52
13/51
De Santis (RCT)
13%
0.87 [0.48-1.56]
death
11/36
25/71
Rojas (SB RCT)
-220%
3.20 [0.64-16.0]
death
46 (n)
45 (n)
COOP-COVID-19-MCTI
Song (RCT)
-52%
1.52 [0.70-3.27]
death
22/87
7/42
CCAP-2
Thorlaci.. (DB RCT)
-76%
1.76 [0.62-5.01]
death
15/98
4/46
PassItOn
Self (DB RCT)
-3%
1.03 [0.73-1.44]
death
89/482
80/465
REMAP-CAP
Higgins (RCT)
1%
0.99 [0.86-1.14]
death
370/944
324/790
ICU patients
Denkinger (RCT)
8%
0.92 [0.75-1.11]
death
68 (n)
66 (n)
CSSC-004
Baksh (DB RCT)
-1%
1.01 [0.94-1.09]
no recov.
381/538
381/532
Alshamrani (PSM)
-14%
1.14 [0.79-1.45]
death
24/41
108/205
Krishnan
-270%
3.70 [0.90-15.8]
death
case control
Tauā
2
ā
= 0.00, Iā
2
ā
= 0.0%, p = 0.88
Late treatment
-0%
1.00 [0.96-1.05]
2,718/11,543
2,672/10,825
0% higher risk
All studies
-0%
1.00 [0.96-1.05]
2,731/12,296
2,682/11,580
0% higher risk
38 convalescent plasma COVID-19 peer reviewed studies
c19
early
.org Sep 2023
Tauā
2
ā
= 0.00, Iā
2
ā
= 0.0%, p = 0.85
Effect extraction pre-specified
(most serious outcome)
Favors conv. plasma
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
INFANT-COVID-19
Libster (DB RCT)
50%
0.50 [0.09-2.65]
death
2/80
4/80
Improvement, RR [CI]
Treatment
Control
INFANT-COVID-19
Libster (DB RCT)
50%
0.50 [0.09-2.65]
ventilation
2/80
4/80
INFANT-COVID-19
Libster (DB RCT)
67%
0.33 [0.07-1.60]
ICU
2/80
6/80
INFANT-COVID-19
Libster (DB RCT)
48%
0.52 [0.29-0.94]
progression
13/80
25/80
Balcells (RCT)
-247%
3.47 [0.35-11.9]
death
5/28
2/30
Balcells (RCT)
-163%
2.63 [0.43-9.10]
ventilation
5/28
2/30
Balcells (RCT)
-23%
1.23 [0.56-1.89]
progression
13/28
12/30
C3PO
Korley (RCT)
-396%
4.96 [0.58-42.2]
death
5/250
1/248
C3PO
Korley (RCT)
10%
0.90 [0.64-1.26]
hosp.
51/257
56/254
C3PO
Korley (RCT)
6%
0.94 [0.72-1.22]
progression
77/257
81/254
Alemany (DB RCT)
80%
0.20 [0.01-4.14]
death
0/188
2/188
Alemany (DB RCT)
-5%
1.05 [0.60-1.84]
hosp.
22/188
21/188
Alemany (DB RCT)
-5%
1.05 [0.85-1.30]
no recov.
188 (n)
188 (n)
Alemany (DB RCT)
-4%
1.04 [0.97-1.11]
viral load
188 (n)
188 (n)
Alemany (DB RCT)
4%
0.96 [0.88-1.05]
viral load
188 (n)
188 (n)
Gharbharan (DB RCT)
-1%
1.01 [0.06-16.0]
death
1/207
1/209
Gharbharan (DB RCT)
67%
0.33 [0.01-8.16]
ventilation
0/207
1/209
Gharbharan (DB RCT)
14%
0.86 [0.59-1.22]
progression
207 (n)
209 (n)
Gharbharan (DB RCT)
42%
0.58 [0.33-1.02]
progression
123 (n)
103 (n)
Gharbharan (DB RCT)
39%
0.61 [0.28-1.34]
hosp.
10/207
18/209
Gharbharan (DB RCT)
-50%
1.50 [0.40-5.64]
hosp. time
207 (n)
209 (n)
Gharbharan (DB RCT)
-1%
1.01 [0.88-1.16]
no recov.
137/207
137/209
Gharbharan (DB RCT)
-8%
1.1 [0.00-9e+04]
recov. time
207 (n)
209 (n)
Li (RCT)
35%
0.65 [0.27-1.39]
death
8/51
12/50
Li (RCT)
15%
0.85 [0.53-1.18]
no improv.
25/52
29/51
Li (RCT)
76%
0.24 [0.07-0.64]
viral+
4/26
15/23
Avendaño-Solà (RCT)
88%
0.12 [0.01-2.11]
death
0/38
4/43
Avendaño-Solà (RCT)
93%
0.07 [0.01-0.57]
progression
0/38
7/43
Avendaño-Solà (RCT)
92%
0.08 [0.01-0.76]
progression
0/38
6/43
PLACID
Agarwal (RCT)
-7%
1.07 [0.73-1.58]
death
34/235
31/229
PLACID
Agarwal (RCT)
-7%
1.07 [0.73-1.58]
progression
44/235
41/229
PLACID
Agarwal (RCT)
1%
0.99 [0.54-1.81]
ventilation
19/227
19/224
PLACID
Agarwal (RCT)
28%
0.72 [0.55-0.95]
viral+
56/173
76/169
Bajpai (RCT)
-323%
4.23 [0.43-41.6]
death
3/14
1/15
Bajpai (RCT)
-114%
2.14 [0.22-21.1]
death
2/14
1/15
Bajpai (RCT)
-221%
3.21 [0.38-27.4]
ventilation
3/14
1/15
Bajpai (RCT)
25%
0.75 [0.55-1.04]
hosp. time
14 (n)
15 (n)
Bajpai (RCT)
32%
0.68 [0.42-1.09]
viral load
14 (n)
15 (n)
AlQahtani (RCT)
50%
0.50 [0.05-5.08]
death
1/20
2/20
AlQahtani (RCT)
33%
0.67 [0.22-2.01]
ventilation
4/20
6/20
AlQahtani (RCT)
22%
0.78 [0.57-1.07]
hosp. time
20 (n)
20 (n)
PlasmAr
Simonovich (RCT)
4%
0.96 [0.50-1.83]
death
25/228
12/105
PlasmAr
Simonovich (RCT)
19%
0.81 [0.50-1.31]
7-point status
228 (n)
105 (n)
Ray (RCT)
33%
0.67 [0.30-1.50]
death
10/40
14/40
RECOVERY
Recovery Co.. (RCT)
0%
1.00 [0.93-1.07]
death
1,399/5,795
1,408/5,763
RECOVERY
Recovery Co.. (RCT)
-1%
1.01 [0.97-1.06]
no disch.
1,963/5,795
1,941/5,763
Gonzalez
-7%
1.07 [0.76-1.50]
death
60/130
26/60
OTā
1
ā
Gonzalez
-1%
1.01 [0.76-1.34]
death
70/130
32/60
OTā
1
ā
Pouladza.. (SB RCT)
40%
0.60 [0.16-2.29]
death
3/30
5/30
Pouladza.. (SB RCT)
-30%
1.30 [0.99-1.71]
hosp. time
30 (n)
30 (n)
Bennett-.. (DB RCT)
19%
0.81 [0.36-1.86]
death
16/59
5/15
Bennett-.. (DB RCT)
11%
0.89 [0.34-2.31]
death
14/59
4/15
Bennett-.. (DB RCT)
0%
1.00 [0.75-1.32]
no improv.
47/59
12/15
Gharbharan (RCT)
4%
0.96 [0.25-2.41]
death
6/43
11/43
Gharbharan (RCT)
12%
0.88 [0.49-1.60]
no disch.
43 (n)
43 (n)
PLACOVID
Sekine (RCT)
-38%
1.38 [0.73-2.63]
death
18/80
13/80
PLACOVID
Sekine (RCT)
-100%
2.00 [0.72-5.59]
death
10/80
5/80
PLACOVID
Sekine (RCT)
-11%
1.11 [0.74-1.66]
no improv.
31/80
28/80
PLACOVID
Sekine (RCT)
-67%
1.67 [0.01-470]
hosp. time
80 (n)
80 (n)
COVIDIT
Kirenga (RCT)
-21%
1.21 [0.51-2.89]
death
10/69
8/67
COVIDIT
Kirenga (RCT)
9%
0.91 [0.38-2.16]
progression
9/41
7/29
COVIDIT
Kirenga (RCT)
-50%
1.50 [0.81-2.77]
viral time
67 (n)
67 (n)
CAPRI
Hsue (DB RCT)
-212%
3.12 [0.14-71.7]
death
1/16
0/18
CAPRI
Hsue (DB RCT)
-12%
1.12 [0.08-16.6]
death
1/16
1/18
CAPRI
Hsue (DB RCT)
-425%
5.25 [0.27-102]
ventilation
2/16
0/18
CAPRI
Hsue (DB RCT)
-425%
5.25 [0.27-102]
progression
2/16
0/18
CAPRI
Hsue (DB RCT)
-425%
5.25 [0.27-102]
progression
2/16
0/18
DAWn-plasma
Devos (RCT)
1%
0.99 [0.52-1.88]
death
320 (n)
163 (n)
DAWn-plasma
Devos (RCT)
-8%
1.08 [0.65-1.80]
ventilation
320 (n)
163 (n)
DAWn-plasma
Devos (RCT)
0%
1.00 [0.74-1.34]
ICU
320 (n)
163 (n)
CONCOR-1
BƩgin (RCT)
-13%
1.13 [0.88-1.45]
death
156/625
69/313
CONCOR-1
BƩgin (RCT)
-12%
1.12 [0.86-1.46]
death
141/614
63/307
CONCOR-1
BƩgin (RCT)
-16%
1.16 [0.94-1.43]
death/int.
199/614
86/307
CAPSID
Kƶrper (RCT)
37%
0.63 [0.33-1.22]
death
11/53
17/52
CAPSID
Kƶrper (RCT)
14%
0.86 [0.34-2.20]
death
7/53
8/52
CAPSID
Kƶrper (RCT)
16%
0.84 [0.62-1.14]
no recov.
30/53
35/52
TSUNAMI
Menichetti (RCT)
23%
0.77 [0.39-1.49]
death
14/231
19/240
TSUNAMI
Menichetti (RCT)
-4%
1.04 [0.62-1.75]
ventilation
25/231
25/240
TSUNAMI
Menichetti (RCT)
12%
0.88 [0.59-1.33]
progression
59/231
67/239
Holm (RCT)
45%
0.55 [0.11-2.84]
death
2/17
3/14
Holm (RCT)
69%
0.31 [0.01-7.09]
ventilation
0/17
1/14
Holm (RCT)
19%
0.81 [0.25-2.64]
progression
4/16
4/13
Holm (RCT)
-57%
1.57 [0.52-4.74]
oxygen time
17 (n)
14 (n)
Holm (RCT)
-62%
1.62 [0.76-3.46]
hosp. time
17 (n)
14 (n)
CONTAIN COVID-19
Ortigoza (DB RCT)
12%
0.88 [0.63-1.20]
death
59/462
71/462
CONTAIN COVID-19
Ortigoza (DB RCT)
1%
0.99 [0.66-1.47]
death
35/463
39/463
CONTAIN COVID-19
Ortigoza (DB RCT)
8%
0.92 [0.74-1.16]
WHO scale
468 (n)
473 (n)
CONTAIN COVID-19
Ortigoza (DB RCT)
6%
0.94 [0.75-1.18]
WHO scale
468 (n)
473 (n)
PennCCP2
Bar (RCT)
81%
0.19 [0.04-0.84]
death
40 (n)
39 (n)
PennCCP2
Bar (RCT)
44%
0.56 [0.24-1.29]
no improv.
40 (n)
39 (n)
PennCCP2
Bar (RCT)
51%
0.49 [0.18-1.30]
ventilation
5/40
10/39
Sullivan (DB RCT)
86%
0.14 [0.01-2.75]
death
0/592
3/589
Sullivan (DB RCT)
25%
0.75 [0.17-3.32]
ICU
3/592
4/589
Sullivan (DB RCT)
54%
0.46 [0.26-0.80]
hosp.
17/592
37/589
Jalili (RCT)
-45%
1.45 [0.74-2.87]
death
16/60
11/60
Jalili (RCT)
-8%
1.08 [0.72-1.63]
ICU
27/60
25/60
Jalili (RCT)
-250%
3.50 [0.76-16.2]
ARDS
7/60
2/60
Jalili (RCT)
-10%
1.10 [0.89-1.36]
hosp. time
60 (n)
60 (n)
Baldeón (DB RCT)
12%
0.88 [0.37-2.11]
death
7/63
12/95
PROTECT-Patient
van den Berg (RCT)
17%
0.83 [0.41-1.68]
death
11/52
13/51
PROTECT-Patient
van den Berg (RCT)
67%
0.33 [0.04-3.04]
ventilation
1/52
3/51
PROTECT-Patient
van den Berg (RCT)
5%
0.95 [0.55-1.63]
no improv.
16/47
18/50
PROTECT-Patient
van den Berg (RCT)
-3%
1.03 [0.62-1.71]
no disch.
18/46
19/50
De Santis (RCT)
13%
0.87 [0.48-1.56]
death
11/36
25/71
De Santis (RCT)
12%
0.88 [0.42-1.82]
death
8/36
18/71
Rojas (SB RCT)
-220%
3.20 [0.64-16.0]
death
46 (n)
45 (n)
Rojas (SB RCT)
38%
0.62 [0.40-0.97]
no disch.
46 (n)
45 (n)
Rojas (SB RCT)
-25%
1.25 [0.36-4.33]
viral+
46 (n)
45 (n)
Rojas (SB RCT)
-16%
1.16 [0.33-4.08]
viral+
46 (n)
45 (n)
Rojas (SB RCT)
-51%
1.51 [0.33-6.98]
viral+
46 (n)
45 (n)
Rojas (SB RCT)
-12%
1.12 [0.16-7.84]
viral+
46 (n)
45 (n)
COOP-COVID-19-MCTI
Song (RCT)
-52%
1.52 [0.70-3.27]
death
22/87
7/42
CORIPLASM
Lacombe (RCT)
49%
0.51 [0.20-1.32]
death
7/60
12/60
CORIPLASM
Lacombe (RCT)
64%
0.36 [0.14-0.97]
death
4/22
11/27
CORIPLASM
Lacombe (RCT)
-68%
1.68 [0.74-3.35]
progression
13/60
8/60
CORIPLASM
Lacombe (RCT)
-4%
1.04 [0.61-1.78]
progression
19/60
20/60
CORIPLASM
Lacombe (RCT)
-7%
1.07 [0.00-9700]
hosp. time
60 (n)
60 (n)
CCAP-2
Thorlaci.. (DB RCT)
-76%
1.76 [0.62-5.01]
death
15/98
4/46
CCAP-2
Thorlaci.. (DB RCT)
-88%
1.88 [0.56-6.33]
death
12/98
3/46
CCAP-2
Thorlaci.. (DB RCT)
-72%
1.72 [0.50-5.87]
death
11/98
3/46
CCAP-2
Thorlaci.. (DB RCT)
-64%
1.64 [0.36-7.60]
death
7/98
2/46
CCAP-2
Thorlaci.. (DB RCT)
-735%
8.35 [0.47-148]
death
5/98
0/46
CCAP-2
Thorlaci.. (DB RCT)
-37%
1.37 [0.29-6.52]
ventilation
6/94
2/43
CCAP-2
Thorlaci.. (DB RCT)
-31%
1.31 [0.45-3.82]
ICU
12/89
4/39
CCAP-2
Thorlaci.. (DB RCT)
-41%
1.41 [0.72-2.09]
7-point status
98 (n)
46 (n)
PassItOn
Self (DB RCT)
-3%
1.03 [0.73-1.44]
death
89/482
80/465
PassItOn
Self (DB RCT)
-26%
1.26 [0.81-1.90]
death
63/482
48/465
PassItOn
Self (DB RCT)
-4%
1.04 [0.82-1.33]
7-point status
487 (n)
473 (n)
REMAP-CAP
Higgins (RCT)
1%
0.99 [0.86-1.14]
death
370/944
324/790
ICU patients
Denkinger (RCT)
8%
0.92 [0.75-1.11]
death
68 (n)
66 (n)
Denkinger (RCT)
-2%
1.02 [0.59-1.77]
ventilation
19/68
18/66
Denkinger (RCT)
22%
0.78 [0.52-1.16]
7-point status
68 (n)
66 (n)
CSSC-004